BRIEF REPORT



Outcomes of Antiviral Retreatment for Immunocompromised Hosts With Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Polymerase Chain Reaction Positivity: A Multicenter Australian Retrospective Case Series

K. A. Bond,^{1,2,3,4,5,0} C. Dendle,^{6,7} S. Guy,^{8,9} M. A. Slavin,^{4,5,10,11} O. Smibert,^{4,12} N. Ibrahim,⁶ P. M. Kinsella,^{3,4,10} C. O. Morrissey,^{7,13} M. A. Moso,^{4,5,a} and J. J. Sasadeusz^{4,5,a}

¹Department of Microbiology, Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia, ²Victorian Infectious Diseases Reference Laboratory, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia, ³Department of Microbiology and Immunology, University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia, ⁴Department of Infectious Diseases, University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia, ⁵Victorian Infectious Diseases Service, The Royal Melbourne Hospital at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia, ⁶Department of Infectious Diseases, Monash Health, Melbourne, Victoria, Australia, ⁷Department of Infectious Diseases, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia, ⁸Department of Infectious Diseases, Eastern Health, Melbourne, Victoria, Australia, ⁹Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia, ¹⁰Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, ¹¹Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia, ¹²Department of Infectious Diseases, Austin Health, Melbourne, Victoria, Australia, and ¹³Department of Infectious Diseases, Alfred Health, Melbourne, Victoria, Australia

Outcomes are presented for a multisite retrospective case series, describing a contemporary cohort of 22 immunocompromised patients with persistent coronavirus disease 2019 (COVID-19) polymerase chain reaction positivity who were retreated with antiviral therapy. For those with data available 14 and 30 days after commencement of antiviral therapy, 41% (9 of 22) and 68% (15 of 22), respectively, cleared COVID-19.

Coronavirus disease 2019 (COVID-19) in immnuocompromised hosts presents with similar signs and symptoms to other

Open Forum Infectious Diseases®

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons. org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact reprints@oup. com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. https://doi.org/10.1093/ofid/ofae449

patient cohorts, but the severity and patient outcomes are generally worse [1]. Immunocompromised hosts are also more likely to experience prolonged viral replication and therefore take longer to be considered noninfectious [2, 3]. As viral culture is not routinely available for most patient samples, a semiquantitative review of positive polymerase chain reaction (PCR) results (eg, PCR cycle threshold [Ct]) is often used to risk stratify patients as to the likelihood of ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication. PCR positivity for SARS-CoV-2 at 21-30 days after initial diagnosis is generally considered persistent positivity, occurring in 15%-25% of patients with hematological cancer [2, 4]. Prolonged PCR positivity may delay the administration of further immunosuppressive therapy/chemotherapy and prolong inpatient isolation precautions [3]. This can, in turn, adversely affect the frequency of medical care, rates of preventable adverse events, and hospital length of stay [5]. Chronic active infection with SARS-CoV-2 may predispose to the development of viral mutations, giving rise to new variants of interest, antiviral resistance, or immune escape [6].

For immunocompromised hosts, COVID-19 directed antiviral therapy is recommended to commence within 5–7 days of initial symptoms, regardless of disease severity [7]. There are currently no treatment recommendations for relapsed or refractory COVID-19. A recent survey of Australasian Infectious Diseases Physicians demonstrated wide heterogeneity in management approaches for persistent COVID-19 PCR positivity, with clinical uncertainty as to (1) the indication for treatment; (2) the preferred antiviral agent; (3) prescription of antivirals as single or combination therapy; and (4) duration of therapy [8]. We sought to describe outcomes for patients with persistent COVID-19 treated with antiviral agents in a multicenter Australian study.

METHODS

Study Setting and Patient Population

A retrospective cohort study was undertaken at 5 tertiary academic hospitals in Melbourne, Australia. Patients were eligible for inclusion if they were (1) immunocompromised [9], (2) received a course of antiviral therapy for persistent COVID-19 between 1 January 2022 and 30 June 2023, and (3) had PCR results available following therapy for persistent COVID-19. During this period Omicron was the dominant variant, emerging in Australia in November 2021 and replacing Delta as the leading cause of COVID-19 infection in early 2022 [10, 11]. Subvariants BA.1 and BA.2 circulated in the first half of 2022, before the emergence of BA.4 and BA.5 in the second half of 2022. Subvariant XBB was predominant in the first half of 2023.

Received 29 May 2024; editorial decision 30 July 2024; accepted 06 August 2024; published online 7 August 2024

^aM. A. M. and J. J. S. contributed equally to this work.

Correspondence: K. A. Bond, MD, Department of Microbiology, Royal Melbourne Hospital at The Peter Doherty Institute for Infection and Immunity, 792 Elizabeth St, Melbourne, Victoria 3100, Australia (katherine.bond@mh.org.au).

Persistent COVID-19 positivity was defined as either a positive PCR result with a Ct value <30 or positive antigen lateral flow assay result \geq 20 days after diagnosis. This corresponded to the timing and threshold used for clearance of immunocompromised patients from respiratory isolation precautions at all institutions, based on local practice and international guidelines [3, 12]. Treatment of persistent COVID-19 infection with a late course of antiviral agents was initiated by treating clinicians under the supervision of local infectious diseases specialists, for the perceived benefit to the patient of improving symptoms or clearing presumed persistent COVID-19 infection. Selection of treatment agent and duration was at the discretion of treating infectious diseases specialists.

SARS-CoV-2 Testing and Study Outcomes

SARS-CoV-2 RT-PCR testing was undertaken at the primary diagnostic laboratories for each site as part of routine clinical care. All laboratories used commercial SARS-CoV-2 PCR assays and were accredited for testing by Australia's National Accreditation Testing Authority (www.nata.com.au). The primary outcome of the study was the proportion of individuals with an indeterminate or negative PCR result or the first of \geq 2 positive sequential PCR results with a Ct value >30 within 14 days of receipt of antiviral therapy for persistent COVID-19. Patients were excluded from outcome analysis if they died within 5 days after treatment initiation or did not have any further SARS-CoV-2 PCR testing after commencement of antiviral therapy.

Data and Ethics Management

Data were retrospectively extracted at each site after review of patient electronic medical records, pharmacy dispensing information systems, and laboratory information systems into a REDCap database. Statistical tests were undertaken using GraphPad Prism software (version 10.2.0).

Patient Consent Statement

This study was approved as a multisite protocol with a waiver of patient consent authorized by the Human Research Ethic Committee from the Royal Melbourne Hospital (no. 2022.236).

RESULTS

Over the study period, 26 patients were prescribed antivirals for persistent COVID-19 of which 22 patients had PCR results available for review (Table 1 and Supplementary Table 1). All patients had previously received ≥ 2 doses of a COVID-19 vaccine (median and interquartile range [IQR], 3), and 86% (19 of 22) had received early directed antiviral therapy for this episode of COVID-19 infection (within 5 days of symptom onset). A persistently positive COVID-19 status required adjustment to planned immunosuppressive therapy in almost half of cases (10 of 22 [46%]). The antiviral therapy and duration selected by treating clinicians for therapy >20 days of COVID-19 was diverse (Table 1 and Figure 1). Both monotherapy (n = 3) and dual therapy (n = 16) was used; 2 patients received sequential monotherapy, and 1 received dual antivirals followed by sequential use of a third agent. No patient received convalescent plasma therapy or additional intravenous immunoglobulin specifically for COVID-19 treatment. The median duration from initial COVID-19 PCR/antigen lateral flow assay diagnosis to late/retreatment with antiviral agents was 35 days (IQR, 29–42 days).

Follow-up PCR results are presented in Figure 1. All followup samples except one (a bronchoalveolar wash sample) were combined deep nasal and oral swab samples. By day 14 after commencement of retreatment antiviral therapy, 41% (9 of 2) had negative results or sequential Ct values >30. Of patients receiving dual therapy, 47% (8 of 17) achieved viral clearance at day 14, compared with none of those receiving single agents (0 of 3) and 1 of 2 receiving sequential therapy. For those receiving dual agents who had PCR result available confirming clearance at any time (82% [14 of 17]), the median time to clearance (IQR) was 9 (5-25) days after the first day of antiviral therapy. For the 4 of 5 patients (80%) receiving either single agents or sequential monotherapy who achieved clearance at any time, the times to clearance were 7, 20, 42, and 46 days, respectively. At 14 days, for those receiving short-course antiviral therapy (≤ 5 days), 50% cleared infection (7 of 4), compared with 25% (2 of 8) of those receiving longer courses of therapy (>5 days). No adverse events were recorded for any participant.

DISCUSSION

Here we describe a contemporary cohort of vaccinated immunosuppressed patients who received treatment for persistent COVID-19 infection, the majority of whom received early directed COVID-19 antiviral therapy at diagnosis (88% [23 of 26]), during a period with reduced efficacy of directed monoclonal antibody therapy. We report a viral clearance rate of 41% (9 of 2) in this cohort at 14 days from antiviral therapy, in comparison with other cohorts of similar size (>10 patients) who have reported success in 30% [13] and 70%-79% [14-16]. In addition to cause of immunosuppression, timing of testing, and treatment heterogeneity, other factors contributing to a lower clearance in this study may relate to (1) study bias toward cases with active SARS-CoV-2 replication rather than residual RNA shedding, due to inclusion of only those with Ct < 30; (2) higher baseline viral loads in respiratory samples, as estimated by a median Ct value of 22, compared with other case series [14]; (3) a majority of case patients who had already received early direct antiviral therapy, compared with studies describing late antiviral therapy in a largely antiviral naive cohort [13–16]; and (4) lower use of directed monoclonal antibody therapy.

 Table 1.
 Clinical Characteristics of 22 Patients Treated With Late or

 Retreatment Coronavirus Disease 2019 Antiviral Therapy for Persistently

 Polymerase Chain Reaction Positive Infection

Age, median (IQR), y 64 (64–74) Male sex 15 (68.2) Immunosuppression 16 (72.7) Renal SOT 2 (9.1) Anti-CD-20 therapy (nonmalignant condition) 4 (18.2) COVID-19 infection details at diagnosis 18 (81.8) Blood cell count, median (IQR), x10°/L WBCs 4.5 (2.9–8.4) Lymphocytes 0.65 (0.38–1.62) Neutrophils 2.9 (1.6–4.5) COVID-19 vaccine doses, median (IQR), no. 3 (3–3) Prior COVID-19 vaccine doses, median (IQR), no. 3 (3–3) Prior tixagevimab-cilgavimab therapy 7 (31.8) Hospital admission 15 (68.2) ICU admission 6 (27.3) COVID-19 therapy at diagnosis MPV MPV 3 (13.6) NIR/r 7 (31.8) RDV 8 (36.4) Brooid 8 (36.4) Bracitinib 1 (4.5) Tixagevimab-cilgavimab 14 (4.5) COVID-19 infection details at late/retreatment AV use 14 (4.5) Time from initial COVID-19 diagnosis, median (IQR), d 35 (29–42)	Characteristic	Patients, No. (%)
Male sex 15 (68.2) Immunosuppression I Hematological condition ^{b,c} 16 (72.7) Renal SOT 2 (9.1) Anti-CD-20 therapy (nonmalignant condition) 4 (18.2) COVID-19 infection details at diagnosis Is (81.8) Blood cell count, median (IQR), x10°/L WBCs 4.5 (2.9-8.4) Lymphocytes 0.65 (0.38-1.62) Neutrophils 2.9 (1.6-4.5) CRP, median (IQR), mg/L 19 (4-48) Prior CVID-19 vaccine doses, median (IQR), no. 3 (3-3) Prior tixagevimab-cilgavimab therapy 7 (31.8) Hospital admission 15 (68.2) ICU admission 6 (27.3) COVID-19 therapy at diagnosis MPV MPV 3 (13.6) NIR/r 7 (31.8) RDV 8 (36.4) MPV + RDV 1 (4.5) Nil AV therapy 3 (13.6) Steroid 8 (36.4) Braceitinib 1 (4.5) Time from initial COVID-19 diagnosis, median (IQR), d 35 (29-42) PCR Ct on 1 of AV use, median (IQR) 2 (20-25)	Age, median (IQR), y	64 (54–74)
Immunosuppression 16 (72.7) Renal SOT 2 (9.1) Anti-CD-20 therapy (nonmalignant condition) 4 (18.2) COVID-19 infection details at diagnosis 18 (81.8) Biodo cell count, median (IQR), x10°/L WBCs WBCs 4.5 (2.9–8.4) Lymphocytes 0.65 (0.38–1.62) Neutrophils 2.9 (1.6–4.5) CRP, median (IQR), mg/L 19 (4–48) Prior tixagevimab-cilgavimab therapy 7 (31.8) Hospital admission 15 (68.2) ICU admission 6 (27.3) COVID-19 therapy at diagnosis 10 (4.5) MPV 3 (13.6) NIR/r 7 (31.8) RDV 8 (36.4) MPV + RDV 1 (4.5) NIR/r 7 (31.8) RDV 8 (36.4) Braccitnib 1 (4.5) Tixagevimab-cilgavimab 1 (4.5) Tixagevimab-cilgavimab 1 (4.5) Tixagevimab-cilgavimab 1 (4.5) COVID-19 infection details at late/retreatment AV use 1 (4.5) Time from initial COVID-19 diagnosis, median (IQR) </td <td>Male sex</td> <td>15 (68.2)</td>	Male sex	15 (68.2)
Hematological condition ^{b.c} 16 (72.7) Renal SOT 2 (9.1) Anti-CD-20 therapy (nonmalignant condition) 4 (18.2) COVID-19 infection details at diagnosis Results available within 48 h after COVID-19 diagnosis 18 (81.8) Blood cell count, median (IQR), x10 ⁹ /L WBCs 4.5 (2.9–8.4) Lymphocytes 0.65 (0.38–1.62) Neutrophils 2.9 (1.6–4.5) CRP, median (IQR), mg/L 19 (4–48) Prior COVID-19 vaccine doses, median (IQR), no. 3 (3–3) Prior tixagevimab-cilgavimab therapy 7 (31.8) Hospital admission 6 (27.3) COVID-19 therapy at diagnosis MPV MPV 3 (13.6) NIR/r 7 (31.8) RDV 8 (36.4) MPV + RDV 1 (4.5) NI AV therapy 3 (13.6) Steroid 8 (36.4) Baracitinib 1 (4.5) Tixagevimab-cilgavimab 1 (4.5) COVID-19 infection details at late/retreatment AV use 10 (45.5) Horge at admission 19 (8.64) ICU admission 7 (31.8) <td>Immunosuppression</td> <td></td>	Immunosuppression	
Renal SOT 2 (9.1) Anti-CD-20 therapy (nonmalignant condition) 4 (18.2) COVID-19 infection details at diagnosis Results available within 48 h after COVID-19 diagnosis 18 (81.8) Blood cell count, median (ICR), ×10°/L WBCs 4.5 (2.9–8.4) Lymphocytes 0.65 (0.38–1.62) Neutrophils 2.9 (1.6–4.5) CRP, median (ICR), mg/L 19 (4–48) Prior COVID-19 vaccine doses, median (IQR), no. 3 (3–3) Prior tixagevimab-cilgavimab therapy 7 (31.8) Hospital admission 15 (68.2) ICU admission 6 (27.3) COVID-19 therapy at diagnosis MPV MPV 3 (13.6) NIR/r 7 (31.8) RDV 8 (36.4) Baracitinib 1 (4.5) Tixagevimab-cilgavimab 1 (4.5) CVID-19 infection details at late/retreatment AV use ^d Asymptomatic 4 (18.2)	Hematological condition ^{b,c}	16 (72.7)
Anti-CD-20 therapy (nonmalignant condition) 4 (18.2) COVID-19 infection details at diagnosis 18 (81.8) Results available within 48 h after COVID-19 diagnosis 18 (81.8) Blood cell count, median (IQR), x10 ⁹ /L WBCs 4.5 (2.9-8.4) Lymphocytes 0.65 (0.38-1.62) Neutrophils 2.9 (1.6-4.5) CRP, median (IQR), mg/L 19 (4-48) Prior CoVID-19 vaccine doses, median (IQR), no. 3 (-3.3) Prior tixagewimab-cilgavimab therapy 7 (31.8) Hospital admission 15 (68.2) ICU admission 6 (27.3) COVID-19 therapy at diagnosis MPV MPV 3 (13.6) NIR/r 7 (31.8) Baracitinib 1 (4.5) NI AV therapy 3 (13.6) Steroid 8 (36.4) Baracitinib 1 (4.5) Tixagewimab-cilgavimab 1 (4.5) COVID-19 infection details at late/retreatment AV use 1 Time from initial COVID-19 diagnosis, median (IQR), d 35 (29-42) PCR Ct on 1 of AV use, median (IQR) 25 (20-25) Hospital admission	Renal SOT	2 (9.1)
COVID-19 infection details at diagnosisResults available within 48 h after COVID-19 diagnosis18 (81.8)Blood cell count, median (IQR), x10 ³ /LVBCs4.5 (2.9–8.4)Lymphocytes0.65 (0.38–1.62)Neutrophils2.9 (1.6–4.5)CRP, median (IQR), mg/L19 (4–48)Prior tixagevimab-cilgavimab therapy7 (31.8)Hospital admission6 (27.3)COVID-19 vaccine doses, median (IQR), no.3 (3–3)Prior tixagevimab-cilgavimab therapy7 (31.8)Hospital admission6 (27.3)COVID-19 therapy at diagnosisMPVMPV3 (13.6)NIR/r7 (31.8)RDV8 (36.4)Baracitinib1 (4.5)Tixagevimab-cilgavimab1 (4.5)Tixagevimab-cilgavimab1 (4.5)COVID-19 infection details at late/retreatment AV useTime from initial COVID-19 diagnosis, median (IQR), d35 (29–42)PCR Ct on d 1 of AV use, median (IQR)22 (20–25)Hospital admission7 (31.8)COVID-19 status10 (45.5)COVID-19 status10 (45.5)COVID-19 status10 (45.5)COVID-19 status10 (45.5)COVID-19 status2 (9.1)Single agent3 (13.6)MPV1 (4.5)NIR/r0 (0)RDV2 (9.1)Sequential single agents2 (9.1)Dual agents at any time17 (77.3)MPV + NIR/r10 (45.5)MPV + NIR/r10 (45.5)MPV + NIR/r10 (45.5)M	Anti–CD-20 therapy (nonmalignant condition)	4 (18.2)
Results available within 48 h after COVID-19 diagnosis 18 (81.8) Blood cell count, median (IQR), ×10 ⁹ /L 4.5 (2.9–8.4) WBCs 0.65 (0.38–1.62) Neutrophils 2.9 (1.6–4.5) CRP, median (IQR), mg/L 19 (4–48) Prior COVID-19 vaccine doses, median (IQR), no. 3 (3–3) Prior tixagevimab-cilgavimab therapy 7 (31.8) Hospital admission 15 (68.2) ICU admission 6 (27.3) COVID-19 therapy at diagnosis 7 (31.8) MPV 3 (13.6) NIR/r 7 (31.8) RDV 3 (13.6) Steroid 8 (36.4) Baracitinib 1 (4.5) Tixagevimab-cilgavimab 1 (4.5) Time from initial COVID-19 diagnosis, median (IQR), diagnosis 35 (29–42) PCR Ct on d 1 of AV use, median (IQR) 22 (20–25) Hospital admission 7 (31.8) COVID-19 status	COVID-19 infection details at diagnosis	
Blood cell count, median (IQR), x10 ⁹ /L 4.5 (2.9–8.4) WBCs 4.5 (2.9–8.4) Lymphocytes 0.65 (0.38–1.62) Neutrophils 2.9 (1.6–4.5) CRP, median (IQR), mg/L 19 (4–48) Prior COVID-19 vaccine doses, median (IQR), no. 3 (3–3) Prior tixagevimab-cilgavimab therapy 7 (31.8) Hospital admission 15 (68.2) ICU admission 6 (2.7) COVID-19 therapy at diagnosis 7 (31.8) MPV 3 (13.6) NIR/r 7 (31.8) RDV 8 (66.4) MPV + RDV 1 (4.5) Nil AV therapy 3 (13.6) Steroid 8 (36.4) Baracitinib 1 (4.5) Time from initial COVID-19 diagnosis, median (IQR), d 35 (29–42) PCR Ct on d 1 of AV use, median (IQR) 22 (20–25) Hospital admission 19 (86.4) ICU admission 7 (31.8) CDVID-19 infection details at late/retreatment AV use 10 (45.5) Hospital admission 19 (86.4) ICU admission 7 (31.8)	Results available within 48 h after COVID-19 diagnosis	18 (81.8)
WBCs 4.5 (2.9–8.4) Lymphocytes 0.65 (0.38–1.62) Neutrophils 2.9 (1.6–4.5) CRP, median (IQR), mg/L 19 (4–48) Prior COVID-19 vaccine doses, median (IQR), no. 3 (3–3) Prior tixagevimab-cilgavimab therapy 7 (31.8) Hospital admission 6 (27.3) COVID-19 therapy at diagnosis 6 (27.3) MPV 3 (13.6) NIR/r 7 (31.8) RDV 8 (36.4) MPV + RDV 1 (4.5) NII AV therapy 3 (13.6) Steroid 8 (36.4) Baracitinib 1 (4.5) Tixagevimab-cilgavimab 1 (4.5) COVID-19 infection details at late/retreatment AV use 10 (45.5) COVID-19 infection details at late/retreatment AV use ^d 7 (31.8) CDVID-19 status 7 (31.8) COVID-19 status 7 (32.8) COVID-19 status 7 (32.8) </td <td>Blood cell count, median (IQR), ×10⁹/L</td> <td></td>	Blood cell count, median (IQR), ×10 ⁹ /L	
Lymphocytes 0.65 (0.38–1.62) Neutrophils 2.9 (1.6–4.5) CRP, median (IQR), mg/L 19 (4–48) Prior COVID-19 vaccine doses, median (IQR), no. 3 (3–3) Prior tixagevimab-cilgavimab therapy 7 (31.8) Hospital admission 15 (66.2) ICU admission 6 (27.3) COVID-19 therapy at diagnosis MPV MPV 3 (13.6) NIR/r 7 (31.8) RDV 8 (36.4) MPV + RDV 1 (4.5) Nil AV therapy 3 (13.6) Steroid 8 (36.4) Baracitinib 1 (4.5) Tixagevimab-cilgavimab 1 (4.5) COVID-19 infection details at late/retreatment AV use Time from initial COVID-19 diagnosis, median (IQR), d 35 (29–42) Hospital admission 19 (8.64) 12 (20–25) Hospital admission 19 (8.64) 10 (45.5) ICU admission 7 (31.8) 13.8) Change or delay to other immunosuppressive therapy 10 (45.5) Single agent 3 (13.6) 14 (50) Single agent 3 (13.6)	WBCs	4.5 (2.9–8.4)
Neutrophils 2.9 (1.6-4.5) CRP, median (IQR), mg/L 19 (4-48) Prior COVID-19 vaccine doses, median (IQR), no. 3 (3-3) Prior tixagevimab-cilgavimab therapy 7 (31.8) Hospital admission 15 (68.2) ICU admission 6 (27.3) COVID-19 therapy at diagnosis 7 (31.8) MPV 3 (13.6) NIR/r 7 (31.8) RDV 8 (36.4) MPV + RDV 1 (4.5) Nil AV therapy 3 (13.6) Steroid 8 (36.4) Baracitinib 1 (4.5) Tixagevimab-cilgavimab 1 (4.5) Tixagevimab-cilgavimab 1 (4.5) COUID-19 infection details at late/retreatment AV use 1 Time from initial COVID-19 diagnosis, median (IQR), d 35 (29-42) PCR Ct on d 1 of AV use, median (IQR) 22 (20-25) Hospital admission 7 (31.8) Change or delay to other immunosuppressive therapy due to COVID-19 status COVID-19 severity at time of late/retreatment AV use ^d Asymptomatic Mild/moderate 11 (50) Severe	Lymphocytes	0.65 (0.38–1.62)
CRP, median (IQR), mg/L19 (4-48)Prior COVID-19 vaccine doses, median (IQR), no.3 (3-3)Prior tixagevinab-cilgavimab therapy7 (31.8)Hospital admission6 (27.3)COVID-19 therapy at diagnosis $(V = 1, 2, 3)$ MPV3 (13.6)NIR/r7 (31.8)RDV8 (36.4)MPV + RDV1 (4.5)Nil AV therapy3 (13.6)Steroid8 (36.4)Baracitinib1 (4.5)Tixagevimab-cilgavimab1 (4.5)Tixagevimab-cilgavimab1 (4.5)COVID-19 infection details at late/retreatment AV useTime from initial COVID-19 diagnosis, median (IQR), d35 (29-42)PCR Ct on d 1 of AV use, median (IQR)22 (20-25)Hospital admission19 (8.64)ICU admission7 (31.8)COVID-19 severity at time of late/retreatment AV use ^d Asymptomatic4 (18.2)Mild/moderate11 (50)Severe/critical7 (32.8)Late/retreatment COVID-19 therapySingle agent3 (13.6)MPV1 (4.5)NIR/r0 (0)RDV2 (9.1)Sequential single agents2 (9.1)Dual agents at any time17 (77.3)MPV + RDV4 (18.2)NIR/r + RDV3 (13.6)MPV + NIR/r10 (45.5)MPV + RDV4 (18.2)NIR/r + RDV3 (13.6)	Neutrophils	2.9 (1.6–4.5)
Prior COVID-19 vaccine doses, median (IQR), no.3 (3–3)Prior tixagevimab-cligavimab therapy7 (31.8)Hospital admission15 (68.2)ICU admission6 (27.3)COVID-19 therapy at diagnosisMPVMPV3 (13.6)NIR/r7 (31.8)RDV8 (36.4)MPV + RDV1 (4.5)Nil AV therapy3 (13.6)Steroid8 (36.4)Baracitinib1 (4.5)Tixagevimab-cligavimab1 (4.5)Tixagevimab-cligavimab1 (4.5)Time from initial COVID-19 diagnosis, median (IQR), d35 (29-42)PCR Ct on d 1 of AV use, median (IQR)22 (20-25)Hospital admission19 (8.64)ICU admission7 (31.8)COVID-19 severity at time of late/retreatment AV use ^d Asymptomatic4 (18.2)Mid/moderate11 (50)Severe/critical7 (32.8)Late/retreatment COVID-19 therapySingle agent3 (13.6)MPV1 (4.5)NIR/r0 (0)RDV2 (9.1)Sequential single agents2 (9.1)Dual agents at any time17 (77.3)MPV + NIR/r10 (45.5)MPV + RDV4 (18.2)NIR/r + RDV3 (13.6)Steroid therapy14 (63.6)Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab3 (13.6)Negative PCR result or sequential Ct >30At d14 after late/retreatment AVs9 (40.9)Dual agents (n = 17)8 (47.0) <td>CRP, median (IQR), mg/L</td> <td>19 (4–48)</td>	CRP, median (IQR), mg/L	19 (4–48)
Prior tixagevimab-cilgavimab therapy 7 (31.8) Hospital admission 15 (68.2) ICU admission 6 (27.3) COVID-19 therapy at diagnosis MPV MPV 3 (13.6) NIR/r 7 (31.8) RDV 8 (36.4) MPV + RDV 1 (4.5) Nil AV therapy 3 (13.6) Steroid 8 (36.4) Baracitinib 1 (4.5) Tixagevimab-cilgavimab 1 (4.5) COVID-19 infection details at late/retreatment AV use Time from initial COVID-19 diagnosis, median (IQR), d PCR Ct on d 1 of AV use, median (IQR) 22 (20-25) Hospital admission 19 (8.64) ICU admission 7 (31.8) Change or delay to other immunosuppressive therapy due to COVID-19 status 10 (45.5) COVID-19 severity at time of late/retreatment AV use ^d Asymptomatic Asymptomatic 4 (18.2) Mild/moderate 11 (50) Severe/critical 7 (32.8) Late/retreatment COVID-19 therapy 3 (13.6) MPV 1 (4.5) NIR/r 0 (0) <td>Prior COVID-19 vaccine doses, median (IQR), no.</td> <td>3 (3–3)</td>	Prior COVID-19 vaccine doses, median (IQR), no.	3 (3–3)
Hospital admission15 (68.2)ICU admission6 (27.3)COVID-19 therapy at diagnosis MPV MPV3 (13.6)NIR/r7 (31.8)RDV8 (36.4)MPV + RDV1 (4.5)Nil AV therapy3 (13.6)Steroid8 (36.4)Baracitinib1 (4.5)Tixagevimab-cilgavimab1 (4.5)COVID-19 infection details at late/retreatment AV useTime from initial COVID-19 diagnosis, median (IQR), d35 (29-42)PCR Ct on d 1 of AV use, median (IQR)22 (20-25)Hospital admission7 (31.8)Change or delay to other immunosuppressive therapy due to COVID-19 status10 (45.5)COVID-19 severity at time of late/retreatment AV used4 (18.2)Asymptomatic4 (18.2)Mild/moderate11 (50)Severe/critical7 (32.8)Late/retreatment COVID-19 therapySingle agent3 (13.6)MPV1 (4.5)NIR/r0 (0)RDV2 (9.1)Sequential single agents2 (9.1)Dual agents at any time17 (77.3)MPV + NIR/r10 (45.5)MPV + NIR/r3 (13.6)Steroid therapy14 (63.6)Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab3 (13.6)Negative PCR result or sequential Ct >30At d14 after late/retreatment AVs9 (40.9)Dual agents (n = 17)8 (47.0)Single or sequential agents (n = 5)1 (20.0)	Prior tixagevimab-cilgavimab therapy	7 (31.8)
ICU admission 6 (27.3) COVID-19 therapy at diagnosis (7) MPV 3 (13.6) NIR/r 7 (31.8) RDV 8 (36.4) MPV + RDV 1 (4.5) Nil AV therapy 3 (13.6) Steroid 8 (36.4) Baracitinib 1 (4.5) Tixagevimab-cilgavimab 1 (4.5) COVID-19 infection details at late/retreatment AV use Time from initial COVID-19 diagnosis, median (IQR), d 35 (29-42) PCR Ct on d 1 of AV use, median (IQR) 22 (20-25) Hospital admission 7 (31.8) Change or delay to other immunosuppressive therapy due to COVID-19 status 10 (45.5) 10 (45.5) COVID-19 severity at time of late/retreatment AV use ^d Asymptomatic 4 (18.2) Mild/moderate 11 (50) Severe/critical 7 (32.8) Late/retreatment COVID-19 therapy Single agent 3 (13.6) MPV 1 (4.5) 11 (50) Sequential single agents 2 (9.1) 1 Sugle agent 3 (13.6) 14.5) MPV 1 (4.5) 11 (4.5) <td>Hospital admission</td> <td>15 (68.2)</td>	Hospital admission	15 (68.2)
COVID-19 therapy at diagnosisMPV3 (13.6)NIR/r7 (31.8)RDV8 (36.4)MPV + RDV1 (4.5)Nil AV therapy3 (13.6)Steroid8 (36.4)Baracitnib1 (4.5)Tixagevimab-cilgavimab1 (4.5)COVID-19 infection details at late/retreatment AV useTime from initial COVID-19 diagnosis, median (IQR), d35 (29-42)PCR Ct on d 1 of AV use, median (IQR)22 (20-25)Hospital admission19 (8.64)ICU admission7 (31.8)Change or delay to other immunosuppressive therapy due to COVID-19 status10 (45.5)COVID-19 severity at time of late/retreatment AV used4 (18.2)Asymptomatic4 (18.2)Mild/moderate11 (50)Severe/critical7 (32.8)Late/retreatment COVID-19 therapy3 (13.6)MPV1 (4.5)NIR/r0 (0)RDV2 (9.1)Sequential single agents2 (9.1)Dual agents at any time17 (77.3)MPV + NIR/r10 (45.5)MPV + RDV4 (18.2)NIR/r + RDV3 (13.6)Steroid therapy14 (63.6)Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab0 (0)Tixagevimab-cilgavimab0 (0)Nixagevimab-cilgavimab0 (0)Tixagevimab-cilgavimab0 (0)Tixagevimab-cilgavimab0 (0)Tixagevimab-cilgavimab9 (40.9)Dual agents (n = 17)8 (47.0)<	ICU admission	6 (27.3)
MPV 3 (13.6) NIR/r 7 (31.8) RDV 8 (36.4) MPV + RDV 1 (4.5) Nil AV therapy 3 (13.6) Steroid 8 (36.4) Baracitinib 1 (4.5) Tixagevimab-cilgavimab 1 (4.5) COVID-19 infection details at late/retreatment AV use 1 Time from initial COVID-19 diagnosis, median (IQR), d 35 (29-42) PCR Ct on d 1 of AV use, median (IQR) 22 (20-25) Hospital admission 19 (8.64) ICU admission 7 (31.8) Change or delay to other immunosuppressive therapy due to COVID-19 status 10 (45.5) COVID-19 severity at time of late/retreatment AV use ^d Asymptomatic Asymptomatic 4 (18.2) Mild/moderate 11 (50) Severe/critical 7 (32.8) Late/retreatment COVID-19 therapy 3 (13.6) MPV 1 (4.5) NIR/r 0 (0) RDV 2 (9.1) Sequential single agents 2 (9.1) Sequential single agents 2 (9.1) Dual agents at any time 17 (77.3) MPV + NIR/r	COVID-19 therapy at diagnosis	
NIR/r 7 (31.8) RDV 8 (36.4) MPV + RDV 1 (4.5) Nil AV therapy 3 (13.6) Steroid 8 (36.4) Baracitinib 1 (4.5) Tixagevimab-cilgavimab 1 (4.5) COVID-19 infection details at late/retreatment AV use 1 Time from initial COVID-19 diagnosis, median (IQR), d 35 (29–42) PCR Ct on d 1 of AV use, median (IQR) 22 (20–25) Hospital admission 19 (8.64) ICU admission 7 (31.8) Change or delay to other immunosuppressive therapy 10 (45.5) due to COVID-19 status 11 (50) Severe/critical 7 (32.8) Late/retreatment COVID-19 therapy 5 Single agent 3 (13.6) MPV 1 (4.5) NIR/r 0 (0) RDV 2 (9.1) Sequential single agents 2 (9.1) Sequential single agents 2 (9.1) Dual agents at any time 17 (77.3) MPV + NIR/r 10 (45.5) MPV + RDV 4 (18.2) <tr< td=""><td>MPV</td><td>3 (13.6)</td></tr<>	MPV	3 (13.6)
RDV 8 (36.4) MPV + RDV 1 (4.5) Nil AV therapy 3 (13.6) Steroid 8 (36.4) Baracitinib 1 (4.5) Tixagevimab-cilgavimab 1 (4.5) COVID-19 infection details at late/retreatment AV use 1 Time from initial COVID-19 diagnosis, median (IQR), d 35 (29–42) PCR Ct on d 1 of AV use, median (IQR) 22 (20–25) Hospital admission 19 (8.64) ICU admission 7 (31.8) Change or delay to other immunosuppressive therapy 10 (45.5) due to COVID-19 status 11 (50) Severe/critical 7 (32.8) Late/retreatment COVID-19 therapy 1 (4.5) NIR/r 0 (0) RDV 2 (9.1) Sequential single agents 2 (9.1) Dual agents at any time 17 (77.3) MPV + NIR/r 10 (45.5) MPV + RDV 4 (18.2) NIR/r + RDV 3 (13.6) Steroid therapy 14 (63.6) Baracitinib 6 (27.3) Tocilizumab 0 (0) Tixagevimab-cilgavimab 0 (0)	NIR/r	7 (31.8)
MPV + RDV1 (4.5)Nil AV therapy3 (13.6)Steroid8 (36.4)Baracitinib1 (4.5)Tixagevimab-cilgavimab1 (4.5)COVID-19 infection details at late/retreatment AV use1 (4.5)COVID-19 infection details at late/retreatment AV use35 (29–42)PCR Ct on d 1 of AV use, median (IQR)22 (20–25)Hospital admission19 (8.64)ICU admission7 (31.8)Change or delay to other immunosuppressive therapy due to COVID-19 status10 (45.5)COVID-19 severity at time of late/retreatment AV used4 (18.2)Asymptomatic4 (18.2)Mild/moderate11 (50)Severe/critical7 (32.8)Late/retreatment COVID-19 therapy3 (13.6)Single agent3 (13.6)MPV1 (4.5)NIR/r0 (0)RDV2 (9.1)Sequential single agents2 (9.1)Dual agents at any time17 (77.3)MPV + NIR/r10 (45.5)MPV + RDV4 (18.2)NIR/r + RDV3 (13.6)Steroid therapy14 (63.6)Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab3 (13.6)Negative PCR result or sequential Ct >30At d 14 after late/retreatment AVs9 (40.9)Dual agents (n = 17)8 (47.0)Single or sequential agents (n = 5)1 (20.0)	RDV	8 (36.4)
Nil AV therapy3 (13.6)Steroid8 (36.4)Baracitinib1 (4.5)Tixagevimab-cilgavimab1 (4.5)COVID-19 infection details at late/retreatment AV useTime from initial COVID-19 diagnosis, median (IQR), d35 (29–42)PCR Ct on d 1 of AV use, median (IQR)22 (20–25)Hospital admission19 (8.64)ICU admission7 (31.8)Change or delay to other immunosuppressive therapy due to COVID-19 status10 (45.5)COVID-19 severity at time of late/retreatment AV used4 (18.2)Asymptomatic4 (18.2)Mild/moderate11 (50)Severe/critical7 (32.8)Late/retreatment COVID-19 therapy3 (13.6)MPV1 (4.5)NIR/r0 (0)RDV2 (9.1)Sequential single agents2 (9.1)Dual agents at any time17 (77.3)MPV + NIR/r10 (45.5)MPV + RDV4 (18.2)NIR/r + RDV3 (13.6)Steroid therapy14 (63.6)Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab0 (0)Tixagevimab-cilgavimab0 (0)Tixagevimab-cilgavimab0 (0)Negative PCR result or sequential Ct >30At d 14 after late/retreatment AVs9 (40.9)Dual agents (n = 17)8 (47.0)Single or sequential agents (n = 5)1 (20.0)	MPV + RDV	1 (4.5)
Steroid $\$$ (36.4)Baracitinib1 (4.5)Tixagevimab-cilgavimab1 (4.5)COVID-19 infection details at late/retreatment AV useTime from initial COVID-19 diagnosis, median (IQR), d35 (29–42)PCR Ct on d 1 of AV use, median (IQR)22 (20–25)Hospital admission19 (8.64)ICU admission7 (31.8)Change or delay to other immunosuppressive therapy due to COVID-19 status10 (45.5)COVID-19 severity at time of late/retreatment AV usedAsymptomaticAsymptomatic4 (18.2)Mild/moderate11 (50)Severe/critical7 (32.8)Late/retreatment COVID-19 therapySingle agent3 (13.6)MPV1 (4.5)NIR/r0 (0)RDV2 (9.1)Sequential single agents2 (9.1)Dual agents at any time17 (77.3)MPV + NIR/r10 (45.5)MPV + RDV4 (18.2)NIR/r + RDV3 (13.6)Steroid therapy14 (63.6)Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab3 (13.6)Negative PCR result or sequential Ct >30At d 14 after late/retreatment AVsAt d 14 after late/retreatment AVs9 (40.9)Dual agents (n = 17)8 (47.0)Single or sequential agents (n = 5)1 (20.0)	Nil AV therapy	3 (13.6)
Baracitinib1 (4.5)Tixagevimab-cilgavimab1 (4.5)COVID-19 infection details at late/retreatment AV useTime from initial COVID-19 diagnosis, median (IQR), d35 (29–42)PCR Ct on d 1 of AV use, median (IQR)22 (20–25)Hospital admission19 (8.64)ICU admission7 (31.8)Change or delay to other immunosuppressive therapy due to COVID-19 status10 (45.5)COVID-19 severity at time of late/retreatment AV usedAsymptomaticAsymptomatic4 (18.2)Mild/moderate11 (50)Severe/critical7 (32.8)Late/retreatment COVID-19 therapySingle agent3 (13.6)MPV1 (4.5)NIR/r0 (0)RDV2 (9.1)Sequential single agents2 (9.1)Dual agents at any time17 (77.3)MPV + NIR/r10 (45.5)MPV + RDV4 (18.2)NIR/r + RDV3 (13.6)Steroid therapy14 (63.6)Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab3 (13.6)Negative PCR result or sequential Ct >304t 0.4 fater late/retreatment AVsAt 0.4 after late/retreatment AVs9 (40.9)Dual agents (n = 17)8 (47.0)Single or sequential agents (n = 5)1 (20.0)	Steroid	8 (36.4)
Tixagevimab-cilgavimab1 (4.5)COVID-19 infection details at late/retreatment AV useTime from initial COVID-19 diagnosis, median (IQR), d35 (29–42)PCR Ct on d 1 of AV use, median (IQR)22 (20–25)Hospital admission19 (8.64)ICU admission7 (31.8)Change or delay to other immunosuppressive therapy due to COVID-19 status10 (45.5)COVID-19 severity at time of late/retreatment AV usedAsymptomaticAsymptomatic4 (18.2)Mild/moderate11 (50)Severe/critical7 (32.8)Late/retreatment COVID-19 therapySingle agent3 (13.6)MPV1 (4.5)NIR/r0 (0)RDV2 (9.1)Sequential single agents2 (9.1)Dual agents at any time17 (77.3)MPV + NIR/r10 (45.5)MPV + RDV4 (18.2)NIR/r + RDV3 (13.6)Steroid therapy14 (63.6)Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab3 (13.6)Negative PCR result or sequential Ct >30At d 14 after late/retreatment AVs9 (40.9)Dual agents (n = 17)8 (47.0)Single or sequential agents (n = 5)1 (20.0)	Baracitinib	1 (4.5)
COVID-19 infection details at late/retreatment AV useTime from initial COVID-19 diagnosis, median (IQR), d35 (29–42)PCR Ct on d 1 of AV use, median (IQR)22 (20–25)Hospital admission19 (8.64)ICU admission7 (31.8)Change or delay to other immunosuppressive therapy due to COVID-19 status10 (45.5)COVID-19 severity at time of late/retreatment AV used4 (18.2)Asymptomatic4 (18.2)Mild/moderate11 (50)Severe/critical7 (32.8)Late/retreatment COVID-19 therapySingle agent3 (13.6)MPV1 (4.5)NIR/r0 (0)RDV2 (9.1)Sequential single agents2 (9.1)Dual agents at any time17 (77.3)MPV + NIR/r10 (45.5)MPV + RDV4 (18.2)NIR/r + RDV3 (13.6)Steroid therapy14 (63.6)Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab3 (13.6)Negative PCR result or sequential Ct >30At d 14 after late/retreatment AVs9 (40.9)Dual agents (n = 17)8 (47.0)Sincle or sequential agents (n = 5)1 (20.0)	Tixagevimab-cilgavimab	1 (4.5)
Time from initial COVID-19 diagnosis, median (IQR), d $35 (29-42)$ PCR Ct on d 1 of AV use, median (IQR) $22 (20-25)$ Hospital admission19 (8.64)ICU admission7 (31.8)Change or delay to other immunosuppressive therapy due to COVID-19 status10 (45.5)COVID-19 severity at time of late/retreatment AV used4 (18.2)Asymptomatic4 (18.2)Mild/moderate11 (50)Severe/critical7 (32.8)Late/retreatment COVID-19 therapySingle agent3 (13.6)MPV1 (4.5)NIR/r0 (0)RDV2 (9.1)Sequential single agents2 (9.1)Dual agents at any time17 (77.3)MPV + NIR/r10 (45.5)MPV + RDV4 (18.2)NIR/r + RDV3 (13.6)Steroid therapy14 (63.6)Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab3 (13.6)Negative PCR result or sequential Ct >30At d 14 after late/retreatment AVs9 (40.9)Dual agents (n = 17)8 (47.0)Single or sequential agents (n = 5)1 (20.0)	COVID-19 infection details at late/retreatment AV use	
PCR Ct on d 1 of AV use, median (IQR)22 (20–25)Hospital admission19 (8.64)ICU admission7 (31.8)Change or delay to other immunosuppressive therapy due to COVID-19 status10 (45.5)COVID-19 severity at time of late/retreatment AV used4 (18.2)Asymptomatic4 (18.2)Mild/moderate11 (50)Severe/critical7 (32.8)Late/retreatment COVID-19 therapySingle agent3 (13.6)MPV1 (4.5)NIR/r0 (0)RDV2 (9.1)Sequential single agents2 (9.1)Dual agents at any time17 (77.3)MPV + NIR/r10 (45.5)MPV + RDV4 (18.2)NIR/r + RDV3 (13.6)Steroid therapy14 (63.6)Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab3 (13.6)Negative PCR result or sequential Ct >30At d 14 after late/retreatment AVs9 (40.9)Dual agents (n = 17)8 (47.0)Single or sequential agents (n = 5)1 (20.0)	Time from initial COVID-19 diagnosis, median (IQR), d	35 (29–42)
Hospital admission19 (8.64)ICU admission7 (31.8)Change or delay to other immunosuppressive therapy due to COVID-19 status10 (45.5)COVID-19 severity at time of late/retreatment AV usedAsymptomaticAsymptomatic4 (18.2)Mild/moderate11 (50)Severe/critical7 (32.8)Late/retreatment COVID-19 therapySingle agent3 (13.6)MPV1 (4.5)NIR/r0 (0)RDV2 (9.1)Sequential single agents2 (9.1)Dual agents at any time17 (77.3)MPV + NIR/r10 (45.5)MPV + RDV4 (18.2)NIR/r + RDV3 (13.6)Steroid therapy14 (63.6)Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab3 (13.6)Negative PCR result or sequential Ct >30At d 14 after late/retreatment AVs9 (40.9)Dual agents (n = 17)8 (47.0)Single or sequential agents (n = 5)1 (20.0)	PCR Ct on d 1 of AV use, median (IQR)	22 (20–25)
ICU admission7 (31.8)Change or delay to other immunosuppressive therapy due to COVID-19 status10 (45.5)COVID-19 severity at time of late/retreatment AV usedAsymptomatic4 (18.2)Mild/moderate11 (50)Severe/critical7 (32.8)Late/retreatment COVID-19 therapy3 (13.6)MPV1 (4.5)NIR/r0 (0)RDV2 (9.1)Sequential single agents2 (9.1)Dual agents at any time17 (77.3)MPV + NIR/r10 (45.5)MPV + RDV4 (18.2)NIR/r + RDV3 (13.6)Steroid therapy14 (63.6)Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab3 (13.6)Negative PCR result or sequential Ct >30At d 14 after late/retreatment AVs9 (40.9)Dual agents (n = 17)8 (47.0)Single or sequential agents (n = 5)1 (20.0)	Hospital admission	19 (8.64)
Change or delay to other immunosuppressive therapy due to COVID-19 status10 (45.5)COVID-19 severity at time of late/retreatment AV used4 (18.2)Asymptomatic4 (18.2)Mild/moderate11 (50)Severe/critical7 (32.8)Late/retreatment COVID-19 therapySingle agent3 (13.6)MPV1 (4.5)NIR/r0 (0)RDV2 (9.1)Sequential single agents2 (9.1)Dual agents at any time17 (77.3)MPV + NIR/r10 (45.5)MPV + RDV4 (18.2)NIR/r + RDV3 (13.6)Steroid therapy14 (63.6)Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab3 (13.6)Negative PCR result or sequential Ct >30At d 14 after late/retreatment AVsQual agents (n = 17)8 (47.0)Single or sequential agents (n = 5)1 (20.0)	ICU admission	7 (31.8)
COVID-19 severity at time of late/retreatment AV usedAsymptomatic4 (18.2)Mild/moderate11 (50)Severe/critical7 (32.8)Late/retreatment COVID-19 therapySingle agent3 (13.6)MPV1 (4.5)NIR/r0 (0)RDV2 (9.1)Sequential single agents2 (9.1)Dual agents at any time17 (77.3)MPV + NIR/r10 (45.5)MPV + RDV4 (18.2)NIR/r + RDV3 (13.6)Steroid therapy14 (63.6)Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab3 (13.6)Negative PCR result or sequential Ct >30At d 14 after late/retreatment AVsAt d 14 after late/retreatment AVs9 (40.9)Dual agents (n = 17)8 (47.0)Single or sequential agents (n = 5)1 (20.0)	Change or delay to other immunosuppressive therapy	10 (45.5)
Asymptomatic4 (18.2)Mild/moderate11 (50)Severe/critical7 (32.8)Late/retreatment COVID-19 therapySingle agent3 (13.6)MPV1 (4.5)NIR/r0 (0)RDV2 (9.1)Sequential single agents2 (9.1)Dual agents at any time17 (77.3)MPV + NIR/r10 (45.5)MPV + RDV4 (18.2)NIR/r + RDV3 (13.6)Steroid therapy14 (63.6)Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab3 (13.6)Negative PCR result or sequential Ct >30At d 14 after late/retreatment AVs9 (40.9)Dual agents (n = 17)8 (47.0)Single or sequential agents (n = 5)1 (20.0)	COVID-19 status	
Normality $+$ (10.2)Mild/moderate11 (50)Severe/critical7 (32.8)Late/retreatment COVID-19 therapySingle agent3 (13.6)MPV1 (4.5)NIR/r0 (0)RDV2 (9.1)Sequential single agents2 (9.1)Dual agents at any time17 (77.3)MPV + NIR/r10 (45.5)MPV + RDV4 (18.2)NIR/r + RDV3 (13.6)Steroid therapy14 (63.6)Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab3 (13.6)Negative PCR result or sequential Ct >30At d 14 after late/retreatment AVs9 (40.9)Dual agents (n = 17)8 (47.0)Single or sequential agents (n = 5)1 (20.0)	Asymptomatic	1 (18 2)
Nink/inductate11 (50)Severe/critical7 (32.8)Late/retreatment COVID-19 therapySingle agent3 (13.6)MPV1 (4.5)NIR/r0 (0)RDV2 (9.1)Sequential single agents2 (9.1)Dual agents at any time17 (77.3)MPV + NIR/r10 (45.5)MPV + RDV4 (18.2)NIR/r + RDV3 (13.6)Steroid therapy14 (63.6)Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab3 (13.6)Negative PCR result or sequential Ct >30At d 14 after late/retreatment AVs9 (40.9)Dual agents (n = 17)8 (47.0)Single or sequential agents (n = 5)1 (20.0)	Mild/moderate	11 (50)
Late/retreatment COVID-19 therapyLate/retreatment COVID-19 therapySingle agent3 (13.6)MPV1 (4.5)NIR/r0 (0)RDV2 (9.1)Sequential single agents2 (9.1)Dual agents at any time17 (77.3)MPV + NIR/r10 (45.5)MPV + RDV4 (18.2)NIR/r + RDV3 (13.6)Steroid therapy14 (63.6)Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab3 (13.6)Negative PCR result or sequential Ct >30At d 14 after late/retreatment AVs9 (40.9)Dual agents (n = 17)8 (47.0)Sincle or sequential agents (n = 5)1 (20.0)	Severe/critical	7 (32 8)
Single agent 3 (13.6) MPV 1 (4.5) NIR/r 0 (0) RDV 2 (9.1) Sequential single agents 2 (9.1) Dual agents at any time 17 (77.3) MPV + NIR/r 10 (45.5) MPV + RDV 4 (18.2) NIR/r + RDV 3 (13.6) Steroid therapy 14 (63.6) Baracitinib 6 (27.3) Tocilizumab 0 (0) Tixagevimab-cilgavimab 3 (13.6) Negative PCR result or sequential Ct >30 At d 14 after late/retreatment AVs At d 14 after late/retreatment AVs 9 (40.9) Dual agents (n = 17) 8 (47.0) Sincle or sequential agents (n = 5) 1 (20.0)	Late/retreatment COVID-19 therapy	, (02.0)
MPV 1 (4.5) NIR/r 0 (0) RDV 2 (9.1) Sequential single agents 2 (9.1) Dual agents at any time 17 (77.3) MPV + NIR/r 10 (45.5) MPV + RDV 4 (18.2) NIR/r + RDV 3 (13.6) Steroid therapy 14 (63.6) Baracitinib 6 (27.3) Tocilizumab 0 (0) Tixagevimab-cilgavimab 3 (13.6) Negative PCR result or sequential Ct >30 At d 14 after late/retreatment AVs At d 14 after late/retreatment AVs 9 (40.9) Dual agents (n = 17) 8 (47.0) Single or sequential agents (n = 5) 1 (20.0)	Single agent	3 (13 6)
NIR/r 0 (0) RDV 2 (9.1) Sequential single agents 2 (9.1) Dual agents at any time 17 (77.3) MPV + NIR/r 10 (45.5) MPV + RDV 4 (18.2) NIR/r + RDV 3 (13.6) Steroid therapy 14 (63.6) Baracitinib 6 (27.3) Tocilizumab 0 (0) Tixagevimab-cilgavimab 3 (13.6) Negative PCR result or sequential Ct >30 At d 14 after late/retreatment AVs 9 (40.9) Dual agents (n = 17) 8 (47.0) Single or sequential agents (n = 5) 1 (20.0)	MPV	1 (4 5)
RDV2 (9.1)Sequential single agents2 (9.1)Dual agents at any time17 (77.3)MPV + NIR/r10 (45.5)MPV + RDV4 (18.2)NIR/r + RDV3 (13.6)Steroid therapy14 (63.6)Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab3 (13.6)Negative PCR result or sequential Ct >30At d 14 after late/retreatment AVs9 (40.9)Dual agents (n = 17)8 (47.0)Single or sequential agents (n = 5)1 (20.0)	NIB/r	0 (0)
Index 2 (9.1)Sequential single agents2 (9.1)Dual agents at any time17 (77.3)MPV + NIR/r10 (45.5)MPV + RDV4 (18.2)NIR/r + RDV3 (13.6)Steroid therapy14 (63.6)Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab3 (13.6)Negative PCR result or sequential Ct >30At d 14 after late/retreatment AVs9 (40.9)Dual agents (n = 17)8 (47.0)Single or sequential agents (n = 5)1 (20.0)	BDV	2 (9 1)
Dual agents at any time 17 (77.3) MPV + NIR/r 10 (45.5) MPV + RDV 4 (18.2) NIR/r + RDV 3 (13.6) Steroid therapy 14 (63.6) Baracitinib 6 (27.3) Tocilizumab 0 (0) Tixagevimab-cilgavimab 3 (13.6) Negative PCR result or sequential Ct >30 4t d14 after late/retreatment AVs At d 14 after late/retreatment AVs 9 (40.9) Dual agents (n = 17) 8 (47.0) Single or sequential agents (n = 5) 1 (20.0)	Sequential single agents	2 (9.1)
MPV + NIR/r 10 (45.5) MPV + RDV 4 (18.2) NIR/r + RDV 3 (13.6) Steroid therapy 14 (63.6) Baracitinib 6 (27.3) Tocilizumab 0 (0) Tixagevimab-cilgavimab 3 (13.6) Negative PCR result or sequential Ct >30 At d 14 after late/retreatment AVs 9 (40.9) Dual agents (n = 17) 8 (47.0) Single or sequential agents (n = 5) 1 (20.0)	Dual agents at any time	17 (77.3)
MPV + RDV4 (18.2)NIR/r + RDV3 (13.6)Steroid therapy14 (63.6)Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab3 (13.6)Negative PCR result or sequential Ct >30At d 14 after late/retreatment AVs9 (40.9)Dual agents (n = 17)8 (47.0)Single or sequential agents (n = 5)1 (20.0)	MPV + NIB/r	10 (45 5)
NIR/r + RDV3 (13.6)Steroid therapy14 (63.6)Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab3 (13.6)Negative PCR result or sequential Ct >30At d 14 after late/retreatment AVs9 (40.9)Dual agents (n = 17)8 (47.0)Single or sequential agents (n = 5)1 (20.0)	MPV + RDV	4 (18.2)
Steroid therapy14 (63.6)Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab3 (13.6)Negative PCR result or sequential Ct >30At d 14 after late/retreatment AVs9 (40.9)Dual agents (n = 17)8 (47.0)Single or sequential agents (n = 5)1 (20.0)	NIB/r + BDV	3 (13.6)
Baracitinib6 (27.3)Tocilizumab0 (0)Tixagevimab-cilgavimab3 (13.6)Negative PCR result or sequential Ct >30At d 14 after late/retreatment AVs9 (40.9)Dual agents (n = 17)8 (47.0)Single or sequential agents (n = 5)1 (20.0)	Steroid therapy	14 (63 6)
Tocilizumab 0 (0) Tixagevimab-cilgavimab 3 (13.6) Negative PCR result or sequential Ct >30 At d 14 after late/retreatment AVs 9 (40.9) Dual agents (n = 17) 8 (47.0) Single or sequential agents (n = 5) 1 (20.0)	Baracitinih	6 (27.3)
Tixagevimab-cilgavimab 3 (13.6)Negative PCR result or sequential Ct >30At d 14 after late/retreatment AVs 9 (40.9)Dual agents (n = 17) 8 (47.0)Single or sequential agents (n = 5) 1 (20.0)	Tocilizumah	0 (0)
Negative PCR result or sequential Ct >30 9 (40.9) At d 14 after late/retreatment AVs 9 (40.9) Dual agents (n = 17) 8 (47.0) Single or sequential agents (n = 5) 1 (20.0)	Tixagevimab-cilgavimab	3 (13.6)
At d 14 after late/retreatment AVs $9 (40.9)$ Dual agents (n = 17) $8 (47.0)$ Single or sequential agents (n = 5) $1 (20.0)$	Negative PCB result or sequential Ct >30	0 (10.0)
Dual agents (n = 17) $8 (47.0)$ Single or sequential agents (n = 5) $1 (20.0)$	At d 14 after late/retreatment AVs	9 (40.9)
Single or sequential agents $(n = 5)$ 1 (20.0)	Dual agents $(n = 17)$	8 (47 0)
	Single or sequential agents $(n = 5)$	1 (20.0)

Table 1. Continued

Characteristic	Patients, No. (%) ^a
Short-total-duration therapy $(n = 14)$	7 (50.0)
Longer-total-duration therapy $(n = 8)$	2 (25.0)
At d 30 after late/retreatment AVs	15 (68.2)

Abbreviations: AV, antiviral; COVID-19, coronavirus disease 2019; CRP, C-reactive protein; Ct, cycle threshold; ICU, intensive care unit; ICR, interquartile range; MPV, molnupirivair; NIR/r, nirmatrelvir/ritonavir; PCR, polymerase chain reaction; RDV, remdesevir; SOT, solid organ transplant; WBCs, white blood cells.

^aData represent no. (%) of patients unless otherwise specified.

^bHematological conditions include lymphoma (n = 7), leukemia (n = 5), hematopoietic stem cell transplant (n = 3), and multiple myeloma (n = 1).

°Five of 18 were also on anti-CD-20 therapy.

^dCOVID-19 severity was defined according to World Health Organization criteria (https://iris. who.int/bitstream/handle/10665/332199/WHO-2019-nCoV-clinical-2020.5-eng.pdf). Mild was defined as symptomatic without clinical signs of pneumonia; moderate, as oxygen saturation (Spo₂) ≥80% at rest on room air with clinical signs of pneumonia (eg, fever, cough, or dyspnea); severe, as Spo₂ <90% at rest on room air, respiratory failure or adult respiratory distress; and critical, as (1) respiratory failure or adult respiratory distress syndrome requiring high-flow nasal oxygen or noninvasive ventilation/intubation or (2) sepsis/septic shock.

In the next-largest cohort, Mikulska et al [16] report that participants who were antiviral naive at the time of late antiviral treatment (59.1% [13 of 22]) were more likely to respond to treatment than the cohort overall (100% [13 of 13] vs 75% [16 of 22]). Two case series with success at 14 days of 30% and 70%, including a majority of patients undergoing COVID-19 retreatment rather than late initial antiviral therapy, used a test of response approach [13, 15]. Antivirals were continued and escalated in a stepwise fashion (remdesivir [RDV] then nirmatrelvir/ritonavir [NIR/r] [15]) or using a variable sequential approach [13] until negative test results were returned. With this approach, response was achieved within 7–36 days for almost all patients.

Clinicians elected to treat the majority of patients in our study (73% [19 of 26]) with dual antiviral therapy. Theoretical benefits of dual therapy include enhanced viral clearance due to a synergistic viricidal activity and the minimization of viral resistance development. Preclinical studies have demonstrated synergy between RDV and molnupiravir in hamster models, RDV and NIR/r in vitro, and NIR/r and molnupiravir in mice and macaque models [17]. Multiple clinical reports describe the success of dual therapy with few adverse effects [16]; however, no head-to-head trials of single versus dual therapy are available. The numbers of patients who received singleagent or sequential therapy were too low in the present study for comparison, but among the few patients who received single-agent or sequential monotherapy the time to clearance was longer than for those receiving dual antiviral therapy (median, 31 vs 9 days respectively). The duration of successful treatment has generally been reported as shorter in cohorts receiving dual therapy [14, 16] than in those receiving sequential monotherapy [13, 15].

The current study is limited by its observational design, the nonuniform follow-up of cases, and the heterogeneity in both



Figure 1. Heat map reporting cycle threshold (Ct) values for real-time polymerase chain reaction (PCR) results for patients receiving a second course of antiviral therapy for persistent coronavirus disease 2019 (COVID-19) infection. Darker colors represent lower Ct values, suggestive of increased amounts of COVID-19 RNA present in samples; lighter colors represent higher Ct values or negative PCR results (N), suggestive of lower amounts of COVID-19 RNA present in samples; numbers in colored boxes reflect the Ct values for the tests, which are provided as a semiquantitative guide and are not directly comparable. Across the 4 health services the following assays were used during the study period: the coronavirus typing assay (AusDiagnostics), Xpert Xpress SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) (Cepheid), Alinity m SARS-CoV-2 (Abbott), and Aptima SARS-CoV-2 Assay (Hologic). Numbers 1–22 represent the case numbers in Supplementary Table 1, which provides additional clinical information by case. Numbers in parentheses represent duration of treatment in days with each agent; numbers in square brackets represent the duration in days of COVID-19 infection from diagnosis to the time of treatment with a late/retreatment course of COVID-19 antiviral therapy. Abbreviations: MPV, molnupiravir (Lagevrio); NIR/r, nirmatrelvir/ritonavir (Paxlovid); RDV, remdesevir (Veklury); RLU, relative light units (output for the Hologic Panther SARS-CoV-2 assay, which are not comparable to Ct values).

the degree of immunosuppression and other host-related factors in this study cohort. The small numbers of patients preclude analysis by type of immunosuppression or other subgroups. Although often used as a semiquantitative measure of viral load, Ct values are not as robust as viral culture or quantitative PCR for determining active viral replication. Use of the Ct value of 30 was based on local clinical practice and international guidelines [3, 12], but this cutoff included some patients may not have had active COVID-19 infection. Conversely, some "cleared" patients may have experienced viral replication, albeit at a lower level, given the rising Ct values over a number of tests. Lower respiratory tract specimens may give a better estimation of viral replication in patients with critical infection, but limited use of bronchoalveolar lavage meant that such samples were not available for testing or inclusion. For outcome analysis it was necessary to define a time period for clearance (14 days), of which only 41% were able to achieve success. However, on review of the treatment response heat map (Figure 1), it can be seen that many of the case patients demonstrated rising Ct values after antiviral therapy but were not tested at designated time intervals that allowed them to be classified as cleared by day 14. This may have underestimated the effect of antivirals. Some asymptomatic or mildly symptomatic patients received antiviral therapy as their persistent COVID-19 infectious status (as defined locally) was affecting their clinical care. This situation may not be generalizable to other settings. The majority of our patients were cleared with a short course of therapy (50%); longer courses were associated with lower clearance rates (25%), suggesting that underlying patient specific factors may have influenced the selection of treatment duration as well as clearance outcome. Nevertheless these data suggests that the extension of therapy beyond 5 days may not be routinely necessary. A reasonable approach may include a test of response at 5 days, with the extension of therapy if predefined Ct criteria are not met.

The current study demonstrates a moderate response to directed antiviral therapy in immunocompromised hosts receiving a retreatment course of antiviral therapy for persistently positive COVID-19 infection. The majority of patients received dual antiviral therapy of short duration. Future studies should focus on this high-risk subgroup, considering both the type and duration of antiviral agents. The low case rate means that a large multicenter randomized control trial will be needed.

Supplementary Data

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgments

The authors acknowledge the clinicians and primary diagnostic laboratories at each health service for the provision of clinical and laboratory information and the clinical care of the patients. For supplementary information relating to diagnostic testing and PCR results, the authors thank Roy Chean MD (Eastern Health) and Tony Korman MD (Monash Health). They also thank the Australian Partnership for Preparedness Research on Infectious Diseases Emergencies (APPRISE) for support with this project.

Author contributions. K. A. B., C. D., S. G., M. A. S., C. O. M., M. A. M., J. J. S., and O. S. conceived, designed and implemented the project. K. A. B., S. G., P. M. K., M. A. M., N. I., and O. S. collected data, while K. A. B. and M. A. M. were involved in data curation. K. A. B. and M. A. M. undertook formal analysis of the data and data visualization. K. A. B., M. A. M., and J. J. S. were responsible for writing the original draft. All authors were involved in review of the manuscript and had access to the original data.

Data sharing statement. The data that support the findings of this study are available from the corresponding author, K. A. B., on reasonable request.

Financial support. This work was supported by The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Victoria Australia (seed grant 2022). Investigators are supported by the following National Health and Medical Research Council grants as follows: postgraduate scholarships GNT1191321 to K. A. B. and GNT2022238 to M. A. M., and investigator grant 1173791 to M. A. S. M. A. S. is also supported by a Synergy grant 2011100. All diagnostic testing and antiviral therapy was undertaken at each health service as part of standard-of-care clinical practice.

Potential conflicts of interest. All authors: No reported conflicts.

References

- Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood 2020; 136:2881–92.
- Lee S, Kim T, Lee E, et al. Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the Republic of Korea. JAMA Intern Med 2020; 180:1447–52.
- Cesaro S, Ljungman P, Mikulska M, et al. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia 2022; 36:1467–80.
- Garcia-Vidal C, Puerta-Alcalde P, Mateu A, et al. Prolonged viral replication in patients with hematologic malignancies hospitalized with COVID-19. Haematologica 2022; 107:1731–5.
- Sprague E, Reynolds S, Brindley P. Patient isolation precautions: are they worth it? Can Respir J 2016; 2016:5352625.
- Hettle D, Hutchings S, Muir P, Moran E. Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: retrospective cohort study and literature review. Clin Infect Pract 2022; 16:100210.
- 7. World Health Organisation. Therapeutics and COVID-19: Living guideline. Geneva, Switzerland: World Health Organization, **2023**.
- Moso MA, Sasadeusz J, Morrissey CO, et al. Survey of treatment practices for immunocompromised patients with COVID-19 in Australasia. Intern Med J 2023; 53:619–24.
- Australian Technical Advisory Group on Immunisation. Recommendations on the use of a 3rd primary dose of COVID-19 vaccine in individuals who are severely immunocompromised. Version 4.2. 2023. Available at: https://www.health.gov. au/resources/publications/atagi-recommendations-on-the-use-of-a-third-primarydose-of-covid-19-vaccine-in-individuals-who-are-severely-immunocompromised? language=en. Accessed 15 April 2024.
- Hadfield J, Megill C, Bell SM, et al. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics 2018; 34:4121–3.
- COVID-19 Epidemiology and Surveillance Team. COVID-19 Australia: epidemiology report 75—reporting period ending 4 June 2023. Commun Dis Intell (2018) 2023:47.
- European Center for Disease Prevention and Control. Guidance on ending the isolation period for people with COVID-19, third update. European Center for Disease Prevention and Control, Sweden, 2022.
- Longo BM, Venuti F, Gaviraghi A, et al. Sequential or combination treatments as rescue therapies in immunocompromised patients with persistent SARS-CoV-2 infection in the Omicron era: a case series. Antibiotics 2023; 12:1460.
- Pasquini Z, Toschi A, Casadei B, et al. Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection. Hematol Oncol 2023; 41:904–11.
- 15. Wada D, Nakamori Y, Maruyama S, et al. Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infection. Exp Hematol Oncol 2022; 11:53.
- Mikulska M, Sepulcri C, Dentone C, et al. Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients. Clin Infect Dis 2023; 77:280–6.
- Focosi D, Maggi F, D'Abramo A, Nicastri E, Sullivan DJ. Antiviral combination therapies for persistent COVID-19 in immunocompromised patients. Int J Infect Dis 2023; 137:55–9.